Repligen Co. (NASDAQ:RGEN) Shares Bought by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC lifted its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 14.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 275,627 shares of the biotechnology company's stock after buying an additional 35,115 shares during the quarter. TimesSquare Capital Management LLC owned approximately 0.49% of Repligen worth $41,019,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Toronto Dominion Bank grew its holdings in Repligen by 1.5% during the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company's stock worth $656,000 after acquiring an additional 75 shares in the last quarter. DekaBank Deutsche Girozentrale increased its holdings in Repligen by 1.1% during the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company's stock valued at $982,000 after buying an additional 89 shares during the period. Ballentine Partners LLC raised its stake in Repligen by 6.2% in the third quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company's stock worth $269,000 after buying an additional 105 shares in the last quarter. Diversified Trust Co lifted its holdings in Repligen by 3.7% during the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock worth $372,000 after buying an additional 106 shares during the period. Finally, CWM LLC lifted its holdings in Repligen by 36.3% during the third quarter. CWM LLC now owns 428 shares of the biotechnology company's stock worth $64,000 after buying an additional 114 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

RGEN has been the subject of a number of analyst reports. Benchmark restated a "hold" rating on shares of Repligen in a research note on Monday, August 5th. UBS Group lowered their price target on shares of Repligen from $205.00 to $185.00 and set a "buy" rating on the stock in a report on Wednesday, July 31st. Stephens reaffirmed an "overweight" rating and issued a $170.00 price objective on shares of Repligen in a research report on Tuesday, July 30th. JPMorgan Chase & Co. increased their target price on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research report on Wednesday, July 31st. Finally, Wells Fargo & Company started coverage on Repligen in a research report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price target on the stock. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Repligen currently has an average rating of "Moderate Buy" and a consensus price target of $190.25.

Repligen Stock Performance

Shares of RGEN traded down $3.18 during trading hours on Friday, reaching $140.70. 543,900 shares of the company traded hands, compared to its average volume of 534,946. The stock has a market capitalization of $7.88 billion, a P/E ratio of -3,516.62, a P/E/G ratio of 4.04 and a beta of 0.96. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The business has a fifty day moving average price of $141.56 and a 200-day moving average price of $145.05. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $211.13.

Insider Activity at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the company's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares of the company's stock, valued at approximately $20,328,540.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.20% of the stock is owned by insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.